CN106692453B - Chinese herbal medicine composition for treating Parkinson's disease and preparation method thereof - Google Patents
Chinese herbal medicine composition for treating Parkinson's disease and preparation method thereof Download PDFInfo
- Publication number
- CN106692453B CN106692453B CN201710087359.0A CN201710087359A CN106692453B CN 106692453 B CN106692453 B CN 106692453B CN 201710087359 A CN201710087359 A CN 201710087359A CN 106692453 B CN106692453 B CN 106692453B
- Authority
- CN
- China
- Prior art keywords
- parkinson
- disease
- granules
- medicine composition
- herbal medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 241000411851 herbal medicine Species 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 239000008187 granular material Substances 0.000 claims abstract description 15
- 241000336316 Cistanche tubulosa Species 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000012153 distilled water Substances 0.000 claims abstract description 4
- 238000004108 freeze drying Methods 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 238000010992 reflux Methods 0.000 claims abstract description 3
- 240000000031 Achyranthes bidentata Species 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 241000005787 Cistanche Species 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 206010034010 Parkinsonism Diseases 0.000 abstract description 8
- 241000405414 Rehmannia Species 0.000 abstract description 6
- 235000013399 edible fruits Nutrition 0.000 abstract description 6
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 238000004140 cleaning Methods 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 240000006766 Cornus mas Species 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 241000209020 Cornus Species 0.000 description 6
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 6
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 6
- 210000003523 substantia nigra Anatomy 0.000 description 5
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 3
- 210000005064 dopaminergic neuron Anatomy 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000000879 optical micrograph Methods 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- 241000405911 Rehmannia glutinosa Species 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 241000219317 Amaranthaceae Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 241000336291 Cistanche deserticola Species 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000142975 Cornaceae Species 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 241000308150 Orobanchaceae Species 0.000 description 1
- 208000030713 Parkinson disease and parkinsonism Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- 208000028752 abnormal posture Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000011859 neuroprotective therapy Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese herbal medicine composition for treating Parkinson's disease and Parkinson's syndrome, which is prepared from four traditional Chinese medicines of prepared rehmannia root, cistanche tubulosa, achyranthes root and dogwood fruit; the invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the steps of cleaning and drying the four traditional Chinese medicines, respectively heating, refluxing and extracting by 4 times of volume of distilled water and 95% ethanol, centrifuging, taking supernate, concentrating in vacuum, freeze-drying the supernate into granules, and mixing 4 granules into granules according to the optimal proportion to obtain the medicinal granules.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a Chinese herbal medicine composition for adjuvant therapy of Parkinson's disease or Parkinson's syndrome.
Background
Parkinson Disease (PD) Parkinson syndrome is a common nervous system degenerative Disease of the middle-aged and the elderly, has high morbidity and disability rate, and seriously harms physical and mental health of patients. Epidemiological investigation shows that the prevalence rate of the Parkinson disease is about 160/10 ten thousands, and only China has about 150 thousands of Parkinson disease patients, and the prevalence rate of the Parkinson disease is on the rise with the aging of population. The clinically major symptoms of PD patients are resting tremor, muscular rigidity, bradykinesia and abnormal posture. Half of patients can not take care of themselves after 5-8 years, and a heavy economic burden is caused to families and society of the patients. Parkinson's disease, although less prevalent than PD, also results in a significant disability rate in the patient.
The traditional Chinese medicine considers that the Parkinson disease and the Parkinson syndrome belong to the scope of 'tremor syndrome' of the traditional Chinese medicine, are caused by internal and external reasons, have complex pathogenesis and are lingering and difficult to cure, and generally the Parkinson disease is considered as deficiency of origin and excess of origin, deficiency of liver and kidney and deficiency of qi and blood, excess of origin is wind, fire, phlegm, stasis and the like.
The treatment of parkinson's disease and parkinsonism syndrome currently mainly involves drug therapy, surgical therapy and gene therapy, of which drug therapy is still clinically predominant. To date, levodopa is still the first choice therapeutic drug for PD, but many side effects, such as 'end-of-dose' and dyskinesia, often appear within 2-5 years of its treatment, so it is important to "neuroprotective therapy" for patients in early stage of PD to save more dopaminergic neurons and delay or even block disease progression.
Therefore, those skilled in the art are devoted to develop a Chinese medicinal composition for adjuvant treatment of Parkinson's disease and Parkinson's syndrome, rescue dopaminergic neurons, and relieve myotonic symptoms and partial non-motor symptoms in patients.
Disclosure of Invention
In view of the above-mentioned drawbacks of the prior art, the technical problem to be solved by the present invention is to provide a herbal composition for treating parkinson's disease, comprising the following as main components:
radix rehmanniae Preparata (rhizome of Rehmannia glutinosa Liboschx. et Mey. or Rehmannia glutinosa Rehmannia (Gaertn.) of Scrophulariaceae)
Cistanche tubulosa (dry fleshy stem with scaly leaves of Cistanche deserticola Y.C.Ma of Orobanchaceae)
Corni fructus (dried mature pulp of Cornus officinalis Sieb. et Zucc. of Cornaceae)
Achyranthes bidentata (a dried root of Achyranthes bidentata blume, Amaranthaceae).
Further, the proportion of the main components is as follows:
radix rehmanniae Preparata of not less than 20% and not more than 50% by weight,
cistanche tubulosa of more than or equal to 20 and less than or equal to 40 weight percent,
dogwood of not less than 15% and not more than 30% by weight,
achyranthes bidentata of not less than 5 and not more than 30 wt%.
Preferably, prepared rehmannia root: cistanche tubulosa: dogwood fruit: achyranthes bidentata 20-30%: 20-30%: 20-30%: 20-30% or prepared rehmannia root: cistanche tubulosa: dogwood fruit: achyranthes bidentata 40-50%: 25-35%: 15-25%: 5 to 10 percent.
Furthermore, the Chinese herbal medicine composition is in the form of granules.
Furthermore, the Chinese herbal medicine composition can be used together with Meiduoba, so that the dosage of the Meiduoba is reduced.
The invention also provides a preparation method of the Chinese herbal medicine composition, which comprises the following steps:
distilling radix rehmanniae Preparata, Cistanchis herba, Corni fructus, and Achyranthis radix with 2-10 times of distilled water and/or ethanol respectively;
centrifuging, collecting supernatant, and concentrating;
freeze drying to obtain granules;
mixing the medicinal granules in the formula in proportion.
The small anti-Parkinson compound provided by the embodiment is proved to have good dopaminergic neuron rescue effect through experimental research, and in clinical application, the recipe can effectively improve the clinical symptoms of patients after being taken for a long time, and the dosage of Meiduoba is reduced.
Technical effects
The Chinese herbal medicine composition provided by the invention has the following effects:
1) delay the progress of the Parkinson's disease and the Parkinson's syndrome;
2) effectively relieve the symptoms of the Parkinson disease and the Parkinson syndrome, particularly the symptoms of slow action and muscular stiffness, and improve the life quality of the patient;
3) effectively cooperate with western medicines (such as MEIDOBA);
4) effectively improve non-motor symptoms in part of patients: such as sweating, constipation, etc.
The preparation method of the Chinese herbal medicine composition provided by the invention can simply and completely extract and store the active ingredients in the Chinese herbal medicines, and can be prepared into granules which are convenient for patients to take with water.
The conception, the specific structure and the technical effects of the present invention will be further described with reference to the accompanying drawings to fully understand the objects, the features and the effects of the present invention.
Drawings
FIG. 1 shows the immunohistochemistry (40-fold lens) of rat substantia nigra tyrosine hydroxylase in a control group in a biological experiment according to a preferred embodiment of the present invention;
FIG. 2 shows the immunohistochemistry (40-fold lens) of rat substantia nigra tyrosine hydroxylase of a model group in a biological experiment according to a preferred embodiment of the present invention;
FIG. 3 shows the immunohistochemical results (40 times lens) of rat substantia nigra tyrosine hydroxylase after model group and Chinese herbal medicine in the biological experiment according to a preferred embodiment of the present invention;
FIG. 4 is an optical microscope image of the frame area of FIG. 1 under a 200 lens magnification;
FIG. 5 is an optical microscope image of the frame area of FIG. 2 under a 200 lens magnification;
FIG. 6 is an optical microscope image of the frame area of FIG. 3 under a 200 lens magnification;
Detailed Description
The following detailed description of embodiments of the invention is intended to be illustrative, and is not to be construed as limiting the invention.
The embodiment provides a Chinese herbal medicine composition which is mainly used for relieving the symptoms of slow movement and muscular stiffness caused by the Parkinson disease or the Parkinson syndrome, improving the life quality of the patient, coordinating western medicines such as Meiduoba and the like, performing synergistic action and reducing the dosage of the western medicines. The Chinese herbal medicine formula comprises the following components: prepared rehmannia root: cistanche tubulosa: dogwood fruit: achyranthes bidentata 10 g: 12 g: 10 g: 10 g. The Chinese herbal medicine formula is granule, which is convenient for patients to carry and take. In another preferred embodiment of the invention, the ratio of the four traditional Chinese medicines is prepared rehmannia root: cistanche tubulosa: dogwood fruit: achyranthes bidentata 14 g: 10 g: 6 g: 2g of the total weight.
The dopamine neuron rescue effect of the small parkinson compound provided by the present example is verified by a biological experiment as follows. In the experiment, about 90 wistar rats of which the weight is about 300g are randomly divided into 9 groups, 1 to 7 groups are small Parkinson compound traditional Chinese medicine intervention observation groups with different medicine proportions, 8 groups are modeling groups, and 9 groups are normal control groups. The medicine proportion of 1-7 groups is uniformly designed U7(74) And arranging experiments to obtain seven formulas. 7 observation groups and model building groups were continuously injected intraperitoneally with rotenone (2.8mg/kg/day) until the Parkinson's disease model was induced. Seven formulas are respectively used 1 week before the injection of rotenoneAnd continuously performing intragastric administration for 5 weeks as an intervention measure, and performing intragastric administration on the modeling group by using physiological saline with the same dose. The weight is measured every two days, and the weight is reduced by 20 percent or the balance beam test is more than or equal to 20s respectively used as an index for evaluating the success of model building of the rat model. Finally, the tyrosine hydroxylase expression of the substantia nigra pars compacta of each group is analyzed by an immunofluorescence method, and statistics indicates that the number of positive neurons of the model group is obviously smaller than that of a control group (p)<0.01), the number of positive cells in the 4 th and 7 th groups of the small compound Parkinson's disease is obviously more than that of the building block (P)<0.05). FIGS. 1-6 show the results of immunohistochemistry for rat substantia nigra Tyrosine Hydroxylase (TH) in control, model plus traditional Chinese medicine, respectively, wherein FIGS. 1-3 are fluorescence micrographs under 40 times lens; FIGS. 4-6 are fluorescence micrographs of the corresponding regions of FIGS. 1-3 taken at 200 Xmagnification, respectively.
Clinical experiments carried out by using the Chinese herbal medicine composition in the embodiment have the following results: patients self-contrast before and after medication, and the group entry standard is as follows: 1) clinical diagnosis is parkinson's disease; 2) Hoehn-Yahr classification is less than or equal to grade III; 3) all have more obvious muscle stiffness symptoms. 30 patients were treated with the formula for 16 weeks in addition to the basic treatment. In 27 patients who finally completed the experiment, the score change of the motor part (UPDRS) according to the unified Parkinson disease score scale before and after traditional Chinese medicine intervention (26.26 +/-5.46 before the traditional Chinese medicine is added and 17.96 +/-6.76 after the traditional Chinese medicine is added) is counted to have significant difference (p is less than 0.001). The prescription is applied to 19 patients with Parkinson's disease with muscle stiffness as a remarkable expression, and symptoms are also remarkably improved.
The embodiment also provides a preparation method of the Chinese herbal medicine composition, and after the four medicinal materials in the composition are qualified through microscopic and thin-layer chromatography (TLC), the four medicinal materials are processed through the following steps:
cleaning, drying and other processing technologies;
heating and refluxing with 4 times of distilled water and 95% ethanol;
centrifuging, and vacuum concentrating the supernatant;
freeze drying to obtain granules;
according to the weight percentage of prepared rehmannia root: cistanche tubulosa: dogwood fruit: achyranthes bidentata 10: 12 g: 10 g: 10g of the mixture, 4 kinds of granules are mixed into granules.
The foregoing detailed description of the preferred embodiments of the invention has been presented. It should be understood that numerous modifications and variations could be devised by those skilled in the art in light of the present teachings without departing from the inventive concepts. Therefore, the technical solutions available to those skilled in the art through logic analysis, reasoning and limited experiments based on the prior art according to the concept of the present invention should be within the scope of protection defined by the claims.
Claims (3)
1. The Chinese herbal medicine composition for treating the Parkinson's disease is characterized by comprising the following components in parts by weight:
radix rehmanniae Preparata of not less than 20% and not more than 50 wt%
Cistanche tubulosa (Desertliving cistanche) Merr of not less than 20% and not more than 40% by weight
Corni fructus of not less than 15% and not more than 30% by weight
Achyranthes bidentata of not less than 5 and not more than 30 wt%.
2. The herbal composition for the treatment of parkinson's disease of claim 1, wherein said herbal composition is in the form of granules.
3. The method of preparing a herbal composition for the treatment of parkinson's disease as set forth in claim 1, comprising the steps of:
extracting radix rehmanniae Preparata, Cistanchis herba, Corni fructus, and Achyranthis radix with 2-10 times of distilled water and/or ethanol under reflux;
centrifuging and taking supernatant;
concentrating;
freeze drying to obtain granules;
mixing the medicinal granules in the formula in proportion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710087359.0A CN106692453B (en) | 2017-02-17 | 2017-02-17 | Chinese herbal medicine composition for treating Parkinson's disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710087359.0A CN106692453B (en) | 2017-02-17 | 2017-02-17 | Chinese herbal medicine composition for treating Parkinson's disease and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106692453A CN106692453A (en) | 2017-05-24 |
| CN106692453B true CN106692453B (en) | 2020-02-18 |
Family
ID=58911784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710087359.0A Active CN106692453B (en) | 2017-02-17 | 2017-02-17 | Chinese herbal medicine composition for treating Parkinson's disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106692453B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474361B (en) * | 2009-01-19 | 2011-03-16 | 河南百年康鑫药业有限公司 | Chinese medicine for treating cerebropathy |
| CN104587052A (en) * | 2015-02-13 | 2015-05-06 | 陈红 | Traditional Chinese medicine combination for Parkinson disease treatment and application thereof |
-
2017
- 2017-02-17 CN CN201710087359.0A patent/CN106692453B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474361B (en) * | 2009-01-19 | 2011-03-16 | 河南百年康鑫药业有限公司 | Chinese medicine for treating cerebropathy |
| CN104587052A (en) * | 2015-02-13 | 2015-05-06 | 陈红 | Traditional Chinese medicine combination for Parkinson disease treatment and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106692453A (en) | 2017-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03003446A (en) | Novel medicinal herbal composition for treating liver diseases and hiv. | |
| CN1836720A (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| WO2006060951A1 (en) | A pharmaceutical composition for the treatment and/or prevention of hyperlipidemia, processes for producing the same and the use thereof | |
| JP2004161732A (en) | Natural medicine preparation for treatment of hiv/aids patient | |
| CN101062080A (en) | Medicinal composition for relieving fatigue and preparing process thereof | |
| CN104208418A (en) | Rosa laevigata michx health oral solution for securing essence, reducing urination and tonifying kidneys and preparation method thereof | |
| CN1289114C (en) | Arthralgia pain treating bolus and its prepn | |
| CN106692453B (en) | Chinese herbal medicine composition for treating Parkinson's disease and preparation method thereof | |
| CN102600370A (en) | Application of Chinese medicinal composition in preparing medicament for preventing and treating Parkinsonism | |
| CN1692938A (en) | Compound traditional Chinese medicine for improving eyesight and its prepn. method | |
| CN114869928A (en) | Traditional Chinese medicine composition for treating cerebrovascular diseases and application thereof | |
| CN1712060A (en) | Preparation of Chinese medicinal mixture for treating gynecologic menstrual disease | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN1775239A (en) | Huanwu detoction for supplementing Yang, its preparing process and use | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN113117012A (en) | Medicine for treating chronic liver injury and preparation method and application thereof | |
| CN1282480C (en) | Head ache capsule preparation | |
| CN1140281C (en) | Yiyuansan powder as one orally taken medicine for treating liver cancer and its preparation | |
| CN1310669C (en) | Medicine composition for treating chronic hepatitis and its prepn | |
| CN1290554C (en) | Medicine used for tonifying-kidney strengthening-yang and replenishing-qi to invigorate the spleen, and its prepn. method | |
| CN1062745C (en) | Shuangshi Zaishengjing oral liquor and preparation method thereof | |
| CN100335111C (en) | Medicine for rheumatism and its preparation | |
| CN1435217A (en) | Bone-strengthening medicine and producing method thereof | |
| CN1634166A (en) | Medicine for treating diabetes and its preparation method | |
| CN112755137A (en) | Traditional Chinese medicine composition for treating mild and moderate knee osteoarthritis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |